Outcomes of SMARCB1-deficient sinonasal carcinoma: Largest single-center cross-sectional study.

Robbie S R Woods Daniel W ScholfieldLucas AxiotakisConall FitzgeraldDauren Adilbay Jennifer R CracchioloSnehal PatelJatin P Shah Lara A DunnDavid PfisterNancy LeeSnjezana DoganIan GanlyMarc Cohen

Published in: Head & neck (2024)

SMARCB1-deficient tumors had limited response to neoadjuvant chemotherapy. Cranial nerve involvement was associated with worse prognosis. Optimal treatment is unclear. Surgery should be offered to patients with resectable disease.

Keyphrases

neoadjuvant chemotherapy
locally advanced
lymph node
sentinel lymph node
minimally invasive
rectal cancer
squamous cell carcinoma
coronary artery bypass
radiation therapy
peripheral nerve
early stage
wild type
acute coronary syndrome
liver metastases
combination therapy
percutaneous coronary intervention